Navigation Links
Diabetes Drug Actos Caused Bladder Cancer and Wrongful Death of Ohio Man, Alleges Lawsuit Filed by Parker Waichman LLP
Date:5/14/2013

New York, New York (PRWEB) May 14, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of the estate of an Ohio man who developed bladder cancer and subsequently died, allegedly from using Actos. The suit was filed on April 2, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0706), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff’s decedent took Actos from June 2002 to February 2007, at about which time he stopped taking the drug and had developed bladder cancer. He died in September 2007 of the bladder cancer, which was allegedly caused by Actos. The Defendants were allegedly aware that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, his doctor and other consumers. The suit seeks damages for extensive pain and suffering, severe emotional distress. Actos’ side effects greatly reduced the Decedent’s ability to enjoy life, the suit alleges.

Actos is a Type 2 diabetes medication that was approved by the U.S. Food and Drug Administration in 1999. In 2011, the agency updated the label to warn that users may face an increased risk of bladder cancer after taking the drug for only one year. (http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm)

Studies have continued to suggest that Actos can increase the risk of bladder cancer. For instance, the May 31, 2012 issue of the British Medical Journal* found that Actos users were twice as likely to develop bladder cancer after two years. In July 3, 2012, the Canadian Medical Association Journal** found that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

*http://www.bmj.com/content/344/bmj.e3645
**http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102

Read the full story at http://www.prweb.com/releases/actos-attorneys/052013/prweb10732524.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PreDiabetes Centers Welcomes Concierge Chef to the Nutrition Team
2. Popular diabetes drug does not improve survival rates after cancer: Study
3. Positive social support at work shown to reduce risk of diabetes
4. PreDiabetes Centers Welcomes Diabetes Guest Blogger to The PreD Blog
5. Dr. Meg Qayum Leads Prediabetes Treatment Center in Houston
6. Faculty List for Continuing Medical Education (CME) Conference 17th Annual Conference on Hypertension, Diabetes and Dyslipidemia Released by Continuing Education Company
7. New mouse model confirms how type 2 diabetes develops
8. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
9. Gastric bypass findings could lead to diabetes treatment
10. How Weight-Loss Surgery Improves Diabetes Control
11. Mileageads Ad Network Now Invites Bloggers and Businesses in the Diabetes Niche to Join their Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration ... Collaborative Residency Network. The platform is scheduled to launch in July 2016 and ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... has been named a Top Doc in Physical Medicine and Rehabilitation by Philadelphia ... Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership across the ...
(Date:4/28/2016)... ... 2016 , ... Starting today, households across the United States ... Prescription Assistance Program. They are customized to reflect the specific health needs of ... ready-to-use, state-themed card and, in the near future, material that highlights savings on ...
(Date:4/28/2016)... ... , ... North Hollywood dentist , Dr. Hamid Reza, now offers emergency ... comes to dental accidents or critical dental problems. These issues can threaten a person's ... knocked-out teeth, chipped teeth, and many other issues can lead to emergency situations, and ...
(Date:4/28/2016)... California (PRWEB) , ... April 28, 2016 , ... For many, a diet is only ... crave it if it does not look good. In addition, an individual cannot deny the ... well. , The team, therefore, has worked to create a product range that could ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... , April 28, 2016 TapImmune,Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for the ... be presenting at the 3rd Annual Growth Capital Expo ... th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... on Wednesday, May 4 th by Dr. John ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology: